Related Experiment Video
Updated: May 5, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Kalliopi Domvri1, Paul Zarogoulidis, Kaid Darwiche
11. Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abstract:
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term "maintenance" treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.
Insights
Lung cancer treatment is shifting towards targeted therapies, but patient selection remains a challenge. This study clarifies maintenance therapy definitions and explores key molecular pathways driving treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Lung cancer treatment evolved from chemotherapy to targeted therapies.
- Limited patient eligibility for targeted therapies due to specific gene mutations.
- Ambiguity in defining second-line versus maintenance therapy in clinical practice.
Purpose of the Study:
- To differentiate between second-line and maintenance therapy in lung cancer treatment.
- To propose a definition for "maintenance" treatment in oncology.
- To review key molecular pathways (EGFR, ALK, MET, PI3K) in lung cancer evolution and treatment resistance.
Main Methods:
- Literature review of current publications and ongoing clinical trials.
- Analysis of molecular pathways implicated in lung cancer progression.
- Correlation of pathway alterations with chemotherapy and targeted therapy efficacy.
Main Results:
- Proposed segregation and definition for maintenance therapy.
- Detailed presentation of EGFR, ALK, MET, and PI3K pathways.
- Discussion on how cancer cell evolution leads to treatment ineffectiveness.
Conclusions:
- Clarifying maintenance therapy can optimize lung cancer treatment strategies.
- Understanding molecular pathways is crucial for overcoming resistance to targeted therapies.
- Future targeted treatments will be informed by ongoing research and clinical trials.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
02:18Cancer
01:29Pharmacogenomics: Identification of New Drug Targets